InVivo gets FDA OK to test bioscaffold in acute SCI patients

04/8/2013 | RTT News

InVivo Therapeutics has received investigational device exemption approval from the FDA to evaluate the use of its biopolymer scaffold in treating patients with acute spinal cord injuries. The study will take place over 15 months, and the company hopes to submit to the FDA the details of the trial by the end of next year.

View Full Article in:

RTT News

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY